Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease

Vivreon Biosciences，LLC 卡罗尔峡谷路4940号套件110 San Diego，CA milton@vivreonbiosciences.com Vivreon Biosciences - NIA SBIR #PA-20-272 -现有NIH赠款的行政补充， 合作协议;特别利益通知（NOSI）：提供技术援助的行政补充 和商业援助（TABA）资助SBIR/STTR获奖者（行政支持）通知编号：NOT-OD-21- 062 项目摘要 Vivreon Biosciences很高兴申请NIA SBIR补充#PA-20-272，以开发知识产权 在我们目前资助的SBIR R44 AG 061995“临床前表征”中， CRAC通道抑制剂用于治疗阿尔茨海默病”。迫切需要补充资金 用于知识产权自由运营（FTO）分析和专利申请。 R44 AG 061995的计划目标是降低我们新的阿尔茨海默病治疗开发候选药物的风险 使该计划成为对第三方投资者和制药合作伙伴有吸引力的投资机会。 为了获得一个非常有前途的可专利的开发候选人，我们的工作流程涉及严格的铅 优化和候选人选择研究。Vivreon药物化学家设计并合成了新的 化学实体（NCE），其计算参数适用于CNS药物，然后对其进行效价测试， ADME和DMPK测定。这些努力已经产生了一种候选治疗方法， 适合进一步发展的特性。Vivreon候选治疗药物具有口服生物利用度， 脑渗透剂，在小鼠和人类AD模型中有效。TABA补充资金迫切需要 需要技术和商业服务来支持知识产权保护。

Vivreon Biosciences, LLC 4940 Carroll Canyon Rd. Suite 110 San Diego, CA 92121 milton@vivreonbiosciences.com Vivreon Biosciences – NIA SBIR #PA-20-272 – Administrative Supplements to Existing NIH Grants and Cooperative Agreements; Notice of Special Interest (NOSI): Administrative Supplement for Providing Technical and Business Assistance (TABA) Funding to SBIR/STTR Awardees (Admin Supp) Notice Number: NOT-OD-21- 062 Project Summary Vivreon Biosciences is pleased to apply for NIA SBIR Supplement #PA-20-272 to develop intellectual property protection for the preclinical candidate in our currently funded SBIR R44AG061995, “Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease”. Supplemental funding is urgently required for intellectual property freedom-to-operate (FTO) analysis and patent filings. The programmatic goal of R44AG061995 is to de-risk our novel Alzheimer’s therapeutic development candidate to make this program an attractive investment opportunity for third-party investors and pharmaceutical partners. To arrive at a highly promising patentable development candidate, our workflow involved rigorous lead optimization and candidate selection studies. Vivreon medicinal chemists designed and synthesized new chemical entities (NCEs) with calculated parameters suitable for a CNS drug, which were then tested in potency, ADME, and DMPK assays. These efforts have yielded a candidate therapeutic that demonstrates drug-like properties appropriate for further development. The Vivreon candidate therapeutic is orally bioavailable, highly brain penetrant, and effective in mouse and human models of AD. TABA supplemental funding is urgently required for technical and business services to support intellectual property protections.